Ollert M W, Söhnchen R, Korting H C, Ollert U, Bräutigam S, Bräutigam W
Department of Dermatology, Ludwig-Maximilians-Universität, Munich, Germany.
Infect Immun. 1993 Nov;61(11):4560-8. doi: 10.1128/iai.61.11.4560-4568.1993.
We established an in vitro adherence model with primarily cultured human keratinocytes as target cells which allows for the investigation of the molecular mechanisms that are responsible for Candida albicans host cell attachment in the initiation of cutaneous candidosis. The extent of C. albicans binding to cultured human keratinocytes was dependent on the yeast inoculum size and the incubation temperature. Heat and paraform-aldehyde treatment of yeasts completely abolished the binding activity of C. albicans. Of the different Candida species tested, C. albicans was by far the most adhesive species. C. albicans adherence was blocked by the acid protease inhibitor pepstatin A and the metabolic inhibitor sodium azide. The latter, however, was much less effective when yeasts were preincubated, suggesting that sodium azide was mainly acting on the keratinocytes. The extracellular matrix protein fibronectin was slightly inhibitory, whereas the fibronectin-derived peptides RGD and RGDS were not able to prevent attachment. PepTite-2000, another RGD-containing synthetic peptide, reduced C. albicans adherence by a margin of 25% (P < 0.005). CDPGYIGSR-NH2, which is a synthetic adhesive peptide derived from the laminin B chain, was much more efficient in its inhibitory activity than the RGD peptides and reduced C. albicans adherence to cultured human keratinocytes up to 76% (P < 0.001). Laminin itself and the synthetic pentapeptide YIGSR were less active. A dose-dependent reduction in adherence was also observed with collagen type III. Additionally, saccharides were tested for their potential to inhibit C. albicans attachment to keratinocytes. The most potent competitive saccharide inhibitors of C. albicans adherence to human keratinocytes were the amino sugars D-(+)-glucosamine and D-(+)-galactosamine with one isolate of C. albicans (4918) and D-(+)-glucosamine and alpha-D-(+)-fucose with another C. albicans isolate (Sp-1). Collectively, our data suggest the existence of multiple molecular mechanisms such as protein-protein, lectin-carbohydrate, and yeast-yeast coaggregational interactions that are responsible for optimal C. albicans attachment to cultured human keratinocytes.
我们建立了一种以原代培养的人角质形成细胞为靶细胞的体外黏附模型,该模型可用于研究皮肤念珠菌病起始阶段白色念珠菌与宿主细胞附着相关的分子机制。白色念珠菌与培养的人角质形成细胞的结合程度取决于酵母接种量和孵育温度。对酵母进行加热和多聚甲醛处理可完全消除白色念珠菌的结合活性。在所测试的不同念珠菌物种中,白色念珠菌是迄今为止黏附性最强的物种。白色念珠菌的黏附被酸性蛋白酶抑制剂胃蛋白酶抑制剂A和代谢抑制剂叠氮化钠所阻断。然而,当酵母预先孵育时,叠氮化钠的效果要差得多,这表明叠氮化钠主要作用于角质形成细胞。细胞外基质蛋白纤连蛋白有轻微抑制作用,而纤连蛋白衍生的肽RGD和RGDS不能阻止附着。另一种含RGD的合成肽PepTite-2000使白色念珠菌的黏附减少了25%(P<0.005)。CDPGYIGSR-NH2是一种源自层粘连蛋白B链的合成黏附肽,其抑制活性比RGD肽更有效,可使白色念珠菌与培养的人角质形成细胞的黏附减少高达76%(P<0.001)。层粘连蛋白本身和合成五肽YIGSR的活性较低。III型胶原也观察到黏附呈剂量依赖性降低。此外,还测试了糖类抑制白色念珠菌附着于角质形成细胞的潜力。对一株白色念珠菌(4918)而言,白色念珠菌黏附于人角质形成细胞的最有效的竞争性糖类抑制剂是氨基糖D-(+)-葡萄糖胺和D-(+)-半乳糖胺;对另一株白色念珠菌(Sp-1)而言,是D-(+)-葡萄糖胺和α-D-(+)-岩藻糖。总体而言,我们的数据表明存在多种分子机制,如蛋白质-蛋白质、凝集素-碳水化合物和酵母-酵母共聚集相互作用,这些机制负责白色念珠菌与培养的人角质形成细胞的最佳附着。